MedTrace Logo

Pregabalin Treatment for Trigger Points

NCT04600037 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2020-10-23

No results posted yet for this study

Summary

Myofascial pain syndrome (MPS) is a common problem in the general population. MPS should not be a local/peripheral painful syndrome and considered to be a syndrome of central sensitivity. We aimed to investigate the effect of pregabalin in patients with MPS in this study

Conditions

  • Myofascial Pain Syndrome

Interventions

DRUG

Pregabalin 150mg

Patients in group I received pregabalin at a dose of 75 mg twice daily during the first week that was increased to 150 mg twice daily thereafter and maintained at that level for 12 weeks. Patients in two groups received exercise therapy (stretching exercises for the trapezius muscle). Patients were instructed to perform 10 repetitions three times a day., 3 months

Sponsors & Collaborators

  • Fatih Sultan Mehmet Training and Research Hospital

    lead OTHER

Principal Investigators

  • Duygu Silte Karamanlioglu, MD · Fatih Sultan Mehmet Training and Research Hospital

  • Duygu Geler Kulcu, prof · Haydarpaşa Numune Training and Research Hospital

  • Gulcan Ozturk, MD · Fatih Sultan Mehmet Training and Research Hospital

  • Pinar Akpinar, Assoc prof · Fatih Sultan Mehmet Training and Research Hospital

  • Feyza Unlu Ozkan, Assoc prof · Fatih Sultan Mehmet Training and Research Hospital

  • Ilknur Aktas, Prof · Fatih Sultan Mehmet Training and Research Hospital

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-26
Primary Completion
2014-07-26
Completion
2015-01-26

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04600037 on ClinicalTrials.gov